Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biota
Biota Raises Relenza Claim to A$564 - A$704 Million (US$485 - US$605 Million)
August 18th, 2007
Biota has filed its updated Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support the influenza drug, Relenza, discovered by Biota and licensed to GSK in 1990. The updated damages assessment filed with the Victorian Supreme Court estimates Biota's losses in the range of A$564 million to A$704 million (US$485 million to US$605 million). The assessment is net of royalties paid to date by GSK to Biota. The initial Particulars of Loss and Damages lodged in July 2005 assessed damages to Biota in the range of A$308 million (US$265 million) to A$430 million (US$370 million). The increase in damages is attributable to a number of...
Source: Law & Health Weekly (2007-08-18)
|
